175204-39-4

Basic information

• Product Name: 4-TERT-BUTYLBENZAMIDOXIME
• Synonyms: 4-TERT-BUTYL-N-HYDROXY-BENZAMIDINE;4-(TERT-BUTYL)-N'-HYDROXYBENZENECARBOXIMIDAMIDE;4-TERT-BUTYLBENZAMIDOXIME;Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-hydroxy- (9CI);4-(tert-Butyl)-N'-hydroxybenzimidamide
• CAS NO: 175204-39-4
• Molecular Formula: C₁₁H₁₆N₂O
• Molecular Weight: 192.26
• Product Categories: AMIDINE;pharmacetical
• Mol File: 175204-39-4.mol
• Article Data: 13

Chemical Properties

• Melting Point: 139-141℃
• Boiling Point: 330.3°Cat760mmHg
• Flash Point: 153.6°C
• Appearance: /
• Density: 1.05g/cm³
• Vapor Pressure: 6.73E-05mmHg at 25°C
• Refractive Index: 1.53
• CAS DataBase Reference: 4-TERT-BUTYLBENZAMIDOXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 4-TERT-BUTYLBENZAMIDOXIME(175204-39-4)
• EPA Substance Registry System: 4-TERT-BUTYLBENZAMIDOXIME(175204-39-4)

Safety Data

• Hazardous Substances Data: 175204-39-4(Hazardous Substances Data)

Usage

General Description

4-Tert-Butylbenzamidoxime is a chemical compound with the molecular formula C11H16N2O. It is an organic compound that belongs to the group of benzamidoximes, which are known for their wide range of biological activities. 4-Tert-Butylbenzamidoxime has been studied for its potential use as a corrosion inhibitor in various industries, as it has shown good inhibitory effects on the corrosion of mild steel in acidic solutions. It is also being researched for its potential use in pharmaceutical applications, as it exhibits antioxidant and anti-inflammatory properties. Additionally, it has been investigated as a potential ligand for metal complexes, due to its ability to coordinate with various metal ions. Overall, 4-Tert-Butylbenzamidoxime is a versatile compound with potential applications in corrosion inhibition, pharmaceuticals, and coordination chemistry.

InChI:InChI=1/C11H16N2O/c1-11(2,3)9-6-4-8(5-7-9)10(12)13-14/h4-7,14H,1-3H3,(H2,12,13)

Upstream product

• 4210-32-6 4-tert-butyl benzonitrile 
• 939-97-9 4-tert-Butylbenzaldehyde 
• 180261-48-7 4-tert-butyl benzene carbaldehyde oxime 

Downstream Products

• 876713-68-7 3-(3-(4-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)-N-methylpropanamide 
• 937650-57-2 3-(3-(4-(tert-butyl)phenyl)-1,2,4-oxadiazol-5-yl)propanoic acid 
• 1570494-34-6 3-(4-(tert-butyl)phenyl)-5-(5-methyl-1-((2-(4-methylpiperazin-1-yl)pyridin-4-yl)methyl)-1H-1,2,4-triazol-3-yl)-1,2,4-oxadiazole 
• 1570494-39-1 3-(4-(tert-butyl)phenyl)-5-(1-((2-chloropyridin-4-yl)methyl)-5-methyl-1H-1,2,4-triazol-3-yl)-1,2,4-oxadiazole 
• 1570494-36-8 3-(4-(tert-butyl)phenyl)-5-(5-methyl-1H-1,2,4-triazol-3-yl)-1,2,4-oxadiazole 
• 1227159-67-2 [3-({4-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-2-methyl-1H-pyrrol-1-yl}methyl)phenyl]-(4-methylpiperazin-1-yl)methanone 

Relevant articles and documents

Development of Potent 3-Br-isoxazoline-Based Antimalarial and Antileishmanial Compounds

Starting from the structure of previously reported 3-Br-isoxazoline-based covalent inhibitors of P. falciparum glyceraldehyde 3-phosphate dehydrogenase, and with the intent to improve their metabolic stability and antimalarial activity, we designed and synthesized a series of simplified analogues that are characterized by the insertion of the oxadiazole ring as a bioisosteric replacement for the metabolically labile ester/amide function. We then further replaced the oxadiazole ring with a series of five-membered heterocycles and finally combined the most promising structural features. All the new derivatives were tested in vitro for antimalarial as well as antileishmanial activity. We identified two very promising new lead compounds, endowed with submicromolar antileishmanial activity and nanomolar antiplasmodial activity, respectively, and a very high selectivity index with respect to mammalian cells.

A cascade process for directly converting nitriles (RCN) to cyanamides (RNHCN) via SO2F2-activated Tiemann rearrangement

A simple, mild and practical process for the direct conversion of nitriles to cyanamides was newly discovered and exhibited a wide substrate scope as well as great functional group-tolerability (36 examples). In this efficient strategy, the in situ generated amidoximes obtained from the reaction of nitriles with hydroxylamine subsequently underwent Tiemann rearrangement, producing the corresponding cyanamides with great isolated yields under SO2F2. Additionally, the control experiments reportedly shed light on the tentative mechanism involved in the formation and elimination of the key intermediate: a sulfonyl ester.

Indazole-oxadiazole derivative, medicinal composition containing derivative, and application of derivative in tumor prevention

The invention discloses an indazole-oxadiazole derivative with the structure represented by general formula a shown in the description, or a pharmaceutically acceptable salt or solvate thereof. In the formula, X is O or N, Y is N, Z is N or O, and all groups are as defined in the description. The invention also discloses a medicinal composition adopting the derivative as an active component, and a use of the derivative. Compounds synthesized in the invention have an HIF-1 inhibition effect, and most of the compounds have a substantial HIF-1 inhibition effect, have strong in-vivo and in-vitro anti-HIF-1 effect on human colorectal carcinoma cell strains (HCT116) and other tumor cell strains, and can be used for treating tumor diseases.